It is well established that tumor neovascularization is necessary for tumor growth and metastatic dissemination (1) . A critical step in the process of neovascularization is local stimulation of endothelial cells by cytokines produced by inflammatory and tumor cells. The endothelial cells then lose their contact inhibition, migrate and breach the basement membrane, proliferate, and differentiate to organize new vessels (2) . Stimulation of endothelial cells by tumor cells is due to an alteration in the balance of angiogenic and antiangiogenic factors (1, 2) . It has become evident that certain drugs with reported antitumor activity have angiogenesis as one of their major targets. Several such factors are effective in maintaining tumor dormancy or even inducing tumor regression (1, (3) (4) (5) .
Somatostatin, a regulatory peptide originally described as an inhibitor of somatotropin release, has a wide range of activities (see ref 6 for review). Somatostatin and its analogs seem to be active in the inhibition of certain tumors (7, 8) . This cyclic peptide binds to seven transmembrane domain, G-protein-coupled receptors that transduce a variety of signals. At least five somatostatin receptor subtypes have been cloned and characterized (9) . All five of these receptor subtypes bind somatostatin 14 and somatostatin 28 (9) . The somatostatin receptors have been reported to affect many different intracellular pathways. For instance, somatostatin has been reported to inhibit cAMP formation, L-type calcium channel activity, and to activate K ϩ channels (6) . In the past few years it has been demonstrated that different somatostatin receptor subtypes are able to induce a phosphotyrosine phosphatase activity that has been proposed to be responsible for the direct antiproliferative activity of this peptide (10, 11) . Inhibitory effects of somatostatin on the growth of various normal and transformed cells have been reported (12) (13) (14) . Tumors of endocrine origin respond to both the direct antiproliferative activity of somatostatin and to the inhibitory effects through reduction of growth factor release (i.e., IGF-I) due to the endocrine activity of somatostatin (8) . An antitumor effect for nonendocrine tumors has also been reported for somatostatin analogs (15) . However, the mechanism for this apparently broad antitumor activity of somatostatin has not been elucidated.
Kaposi's sarcoma (KS) 2 is a highly angiogenic lesion frequently associated with AIDS. The products of KS cells are highly angiogenic in vivo (16) and induce endothelial cell migration and invasion in vitro (17) . The HIV-Tat product also shows a potent angiogenic activity (18, 19) that is mediated by specific binding and activation of the KDR receptor for VEGF (20) . Here we report that somatostatin inhibits KS tumor cell growth in vitro and in vivo. However, the KS cells used did not express any known somatostatin receptors and did not respond to somatostatin in vitro. Instead, tumor growth inhibition was associated with a block of the angiogenesis and stimulation of endothelial cells and monocytes by the KS cells.
MATERIALS AND METHODS

Materials
Synthetic HIV-1 Tat protein (Tecnogen) was dissolved in phosphate-buffered saline (PBS) 0.1% bovine serum albumin (BSA), aliquoted, and stored at Ϫ80°C. Tat purity was tested in Western blot analysis (silver staining) and Tat was used in the dark at 4°C to avoid degradation. Matrigel was purified from the EHS tumor as described previously (21) and is commercially available from Collaborative Biomedical Products. Heparin (Clarisco, Schwarz Pharma S.p.A.) was added as indicated. Somatostatin (Nova Biochem) was dissolved in sterile dH 2 O at 1 mM and stored at Ϫ80°C.
Cells
The human endothelial-like immortalized cell-line EAhy926, derived from the fusion of human umbilical vein endothelial (HUVE) cells with the A549 cell line, has been shown to have an endothelial-like phenotype (22) . These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 10% FCS h.i. (Seromed), supplemented with glutamine (300 g/ ml), penicillin (100 U/ml), and streptomycin (50 g/ml). Primary cultures of KS spindle cells (23) were grown in 50% DMEM and 50% RPMI 1640, 10% FCS supplemented with glutamine (300 g/ml). KS-Imm cells were isolated by our laboratory from a kidney transplanted immunosuppressed patient and have been described previously (24) . HUVE cells from the ATCC (Rockville, Md.) were cultivated on gelatincoated plates (1,5% in PBS) in M199 containing 10% heatinactivated fetal calf serum, 100 g/ml heparin, and 60 g/ml endothelial cell growth factor (ECGS; crude extract isolated from bovine brain) at 37°C in a 5% CO 2 .
Tumor growth in vivo
KS-Imm cells (5 ϫ 10 6 cells) (24) were mixed with liquid Matrigel to a final volume of 250 l at 4°C and injected subcutaneously (s.c.) in the flanks of nude (nu/nu) mice. The animals were housed in pathogen-free conditions; mice were weighed and tumor growth was monitored by measuring tumor size every day (25) . Treated animals had 50 g of somatostatin injected s.c. twice daily. Controls received an injection of buffer alone. Animals were killed after 20 days and the tumors removed, photographed, and processed for histology.
In vivo angiogenesis
We used the Matrigel sponge model of angiogenesis introduced by Passaniti (26) and modified Albini (16) . Somatostatin was mixed with Tat, tumor necrosis factor ␣ (TNF-␣), and heparin and added to unpolymerized liquid Matrigel at 4°C to a final volume of 600 l. The Matrigel suspension was slowly injected s.c. into the flank of C57/bl6 male mice with a cold syringe. In vivo, the gel quickly polymerizes to form a solid gel. Matrigel with buffer alone was used as negative control. After 4 days, gels were collected and weighed. Some of the samples were minced and diluted in water to measure the hemoglobin content with a Drabkin reagent kit (Sigma, St. Louis, Mo.) that was normalized to 100 mg of recovered gel and confronted with a standard curve of mouse blood hemoglobin. Other samples were fixed in formalin, embedded in paraffin, and sections were stained with hematoxylin and eosin for histological analysis.
Chemotaxis and invasion assays
These assays were carried out in Boyden chambers as described by Postlethwaite (27) and modified by Albini (28) . EAhy926 cells were harvested in trypsin/EDTA solution (0.05/0.02% in PBS, Seromed), collected by centrifugation, and resuspended in DMEM 0.1% BSA. The lower compartment of Boyden chambers (200 l) was filled with the chemoattractants: KS-conditioned medium or Tat protein (10 ng/ml) with TNF-␣ with heparin (0.01 U/ml) diluted in DMEM with 0.1% BSA. DMEM with 0.1% BSA alone (SFM) was used as negative control to evaluate random migration. EAhy926 cells (1.2 ϫ 10 5 /400 l per chamber) were placed in the upper compartment along with somatostatin at the concentrations indicated. The two compartments were separated by a polycarbonate filter (12 m pore size; Nucleopore, Milan, Italy) coated with gelatin to allow for cell adhesion. Chambers were incubated for 6 h at 37°C in humidified atmosphere containing 5% CO 2 . After incubation, cells on the upper side of the filter were removed. The cells migrated to the lower side of the filter were fixed in 100% ethanol, stained with toluidine blue, and 5 to 8 unit fields per filter were counted at 160ϫ magnification with a microscope (Zeiss). The test was run in triplicate and repeated six times. In the chemoinvasion assay, Matrigel was added to the filters as a barrier (28).
Growth assays
[ 3 H]-Thymidine incorporation assay
DNA synthesis activity was measured by means of the [ 3 H]-thymidine uptake assay as previously reported (29) . Briefly, cells were plated at the density of 5 ϫ 10 5 in 24-well plates. After 24 h, cells were serum-and growth factor-starved for 48 h. Subsequently, cells were treated with the test substances for 16 h, and in the last 4 h cells were pulsed with 2 Ci/ml of [ 3 H]-thymidine (Amersham). At the end of the incubation time, cells were trypsinized (15 min at 37°C), extracted in 10% trichloroacetic acid (TCA) and filtered under vacuum through fiber glass filters (GF/A; Whatman). The filters were then washed sequentially under vacuum with 10% and 5% TCA and 95% ethanol. The TCA-insoluble fraction was then counted in a scintillation counter.
MTT-assay
Mitochondrial function, as an index of cell viability, was evaluated by measuring the levels of mitochondrial dehydrogenase activity using reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5, diphenyl tetrazolium bromide (MTT) as the substrate. Its cleavage to a purple formazan product by dehydrogenase was quantified spectrophotometrically measuring the absorbance at 570 nm.
Isolation of monocytes
Heparinized peripheral blood from normal, HIV-negative healthy donors was carefully layered on the top of an equal volume of Ficoll (Seromed, Berlin, Germany) and centrifuged at 600 ϫ g for 40 min. After centrifugation, the mononuclear cells (peripheral blood mononuclear cells) remaining at the sample/medium interface were collected and purified on Percoll (Pharmacia-Biotech, Milan, Italy).
Chemotaxis assays for monocytes
Chemotaxis was performed in a 48-microwell chemotaxis chamber (Costar-Nucleopore), using a 5 M pore-size polyvinylpyrrolidone-free polycarbonate filter (Costar-Nucleopore) that divides each well in two compartments (30 -32) . The lower compartment was filled with 27 l of chemoattractant (Tat or KS-CM) diluted in RPMI 0.1% BSA. The concentration of f-MLP inducing maximal migration, 10 Ϫ8 M, was used as the positive control. Simple RPMI/0.1% BSA was the negative control to evaluate background migration. The upper compartment was filled with 50 l of monocytes (10 7 cells/ml) suspended in RPMI/0.1% BSA. The chamber was incubated at 37°C in 5% CO 2 humidified atmosphere for 120 min. Somatostatin was added to the cell suspension 1 h before running the assay. Each point was run in sextuplicate. The filter was then removed and the cells fixed with absolute ethanol and stained with toluidine blue. Cells that had not migrated were removed from the upper surface of the filter using filter paper. Migration was assessed by scanning the filters and quantitation by using the NIH Image program as described previously (32) .
Polarization assay
The ability of somatostatin to inhibit monocyte polarization was assessed following the procedure of Locati et al. (33) , with minor modifications (32) . Freshly Percoll-purified monocytes (5 ϫ 10 5 /500 l) were preincubated at 37°C in polypropylene tubes for 5 min and then treated with polarizing stimuli for 10 -30 min. The assay was stopped by adding an equal volume of cool 10% formaldehyde in PBS. The percent of polarized monocytes was determined by seeding 10 l of cell suspension in a Bürker hemocytometer and counting the number of polarized cells over the total number of cells by microscopy.
Detection of somatostatin receptors
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using the acidic phenol technique (34) , treated for 45 min with RNase-free Dnase, then phenol/ chloroform extracted and ethanol precipitated. cDNA was synthesized using AMV RT (Finnzyme OY, Finland) with oligo dT (16) primers. Ten nanograms of cDNA was subsequently used in the PCR reaction for 35 cycles (1 min at 94°C, 1 min at 60°C, and 1 min at 72°C, followed by 7 min at 72°). Amplified DNA fragments were visualized by 1.7% agarose gel electrophoresis. The primers used were SSTR1: 5Ј-sense primer corresponding to amino acids 225-244 and the 3Ј-antisense primer corresponding to amino acids 438 -457 of the SSTR1 sequence; SSTR2: the 5Ј-sense primer corresponding to amino acids 71-77 and the 3Ј-antisense primer corresponding to amino acids 195-201 of the SSTR2 sequence; SSTR3: the 5Ј-sense primer corresponding to amino acids KS-Imm cells sham treated (e) or treated twice daily with somatostatin (OE). Average tumor size is shown, differences in tumor sizes of the two groups were statistically significant from 14 days on to the end of the experiment (PϽ0.03). b) Average mouse weight (Ϯ sd) of animals treated with or without somatostatin, no differences were observed. c) RT-PCR of somatostatin receptors from mRNA of KS-Imm cells. None of the primers for SSTR 1-5 amplified a product, whereas the control ␤-actin primers amplified the expected product, confirming sample integrity. d) KS-Imm cell growth in vitro with (E) or without (f) somatostatin, as assessed by the MTT assay; no significant differences were observed.
663-682 and the 3Ј-antisense primer corresponding to amino acids 865-884 of the SSTR3 sequence; SSTR4: the 5Ј-sense primer corresponding to amino acids 548 -567 and the 3Ј-antisense primer corresponding to amino acids 849 -868 of the SSTR4 sequence; SSTR5: the 5Ј-sense primer corresponding to amino acids 598 -617 and the 3Ј-antisense primer corresponding to amino acids 801-820 of the SSTR5 sequence; expected lengths for the amplified products were the following: SSTR1 ϭ 233bp, SSTR2 ϭ 402bp, SSTR3 ϭ 222bp; SSTR4 ϭ 321bp, SSTR5 ϭ 235bp.
RESULTS
Somatostatin inhibition of Kaposi's sarcoma tumor growth
The KS-Imm line is an immortalized Kaposi's sarcoma cell line (24) that forms highly angiogenic and hemorrhagic tumors when injected s.c. in nude mice. A twice daily treatment with 50 g somatostatin significantly reduced tumor growth as compared with controls (Fig. 1a) . Large tumors formed in 90% of the injected controls, while all the treated animals had tumors that formed slowly and were strictly limited in size. No differences were noted in animal body weights, indicating limited toxicity of the somatostatin treatment (Fig. 1b) .
The strong inhibition of KS-Imm tumor growth by somatostatin suggested that these cells have receptors for somatostatin. However, RT-PCR experiments demonstrated that the KS-Imm cells do not express any of the known somatostatin receptors (Fig. 1c) . Somatostatin did not affect KS-Imm cell growth in vitro (Fig. 1d) , further suggesting that the response was not directly mediated by receptors for somatostatin on KS cells. Histological examination of the tumors showed extensive vascularization in the control, but the somatostatin-treated tumors showed very little vascularization (Fig. 2a) . Since angiogenesis is required for solid tumor growth, we examined the effects of somatostatin on KS cell product-induced angiogenesis.
Inhibition of angiogenesis in vivo
KS cell products induce a potent angiogenic reaction in vivo, with an intense infiltration of new vessels, as readily seen in macroscopic examination. Addition of somatostatin to the Matrigel containing KS cell products clearly blocked this angiogenic response (Fig. 2b) . Quantitation of angiogenesis by hemoglobin content showed that somatostatin significantly (PϽ0.001) reduced the angiogenic response ( Table 1) .
We have previously demonstrated that HIV-Tat induces angiogenesis through the VEGF flk1/KDR receptor on endothelial cells (20) . This induction of angiogenesis by Tat appears to use a pathway different than that of KS-CM, as the metalloproteinase inhibitor TIMP-2 is able to block KS cell productinduced angiogenesis but not that of HIV-Tat (16). Exposure to TNF-␣ increases KDR levels on endothelial cells by 5-to 10-fold (35) and enhances the response to Tat. We therefore used Tat in combination with TNF-␣ as a powerful angiogenic mixture in vivo. Somatostatin strongly inhibited the angiogenesis induced by TNF-␣ and Tat (Fig. 2c) . Histological examination confirmed the absence of vascularization in the somatostatin-treated samples for both Tat/TNF-␣/heparin (Fig. 2d) and KS-CM/heparin (not shown). Determination of hemoglobin content also demonstrated a significant inhibition of Tat/ TNF-␣/heparin-induced angiogenesis by somatostatin ( Table 1 ). The addition of vanadate, an inhibitor of phosphotyrosine phosphatases, counteracted the effect of somatostatin, suggesting that activation of phosphotyrosine phosphatases is involved in the somatostatin inhibition of Tat-induced angiogenesis. (Table 1) Angiogenesis inhibitors can act through a number of effector targets. They can block endothelial cell growth and or their migration. In addition, angiogenesis inhibitors could also act indirectly on other effector cell types, such as monocytes, which appear to play a key role in angiogenesis. We tested the effects of somatostatin in vitro on stimulated endothelial cells and on monocytes.
Somatostatin effects on endothelial cells
Treatment with somatostatin inhibited the growth of endothelial cells stimulated with KS cell products (Fig. 3a) . This effect was observed in primary cultures of umbilical vein endothelial cells (HUVEC, not shown) and in the human endothelial-like immortalized cell-line EAhy926 (Fig. 3a) . The inhibitory effects of somatostatin on cell proliferation was reverted by the pretreatment with vanadate (50 M), thus confirming the involvement of phosphotyrosine phosphatases in the somatostatin antiproliferative activity of endothelial cells. Vanadate alone increases cell growth due to repression of endogenous phosphatases, as previously observed (14, 29) .
During angiogenesis endothelial cells must migrate and invade through their own basement membrane (2), a major barrier to cell movement (28) . Induction of an invasive phenotype in endothelial cells in vitro is a hallmark of the angiogenic response in vivo, and KS cell products induce endothelial cell invasion through a reconstituted basement membrane in vitro in the chemoinvasion assay (17) . Somatostatin added to the upper chamber dosedependently inhibited the ability EAhy926 cells to invade in response to KS cell products (Fig. 3b) . This inhibition was selective for invasion, as migration in the absence of the basement membrane barrier was not affected (not shown).
Endothelial cells express only the SSTR3 somatostatin receptor, as assessed by RT-PCR analysis (Fig.  3c) . These data indicate that somatostatin directly affects the endothelial response to KS cell product stimulation. In contrast to KS cell products, somatostatin was not able to reduce Tat/TNF-␣-induced endothelial cell invasion (not shown). These data confirm that KS cell product and Tat-induced angiogenesis occur through independent pathways. However, somatostatin effectively blocked Tat-TNF-␣ angiogenesis in vivo (Fig. 2c, Table 1 ), indicating that it may effect a different target.
Monocytes/macrophages also appear to be major mediators of angiogenesis (36) . Monocytes infiltrate early in response to angiogenic stimuli and subsequently produce factors that stimulate endothelial cells to form new vessels. Inhibition of monocyte recruitment could also inhibit tumor-induced angiogenesis. Since Tat potently induces monocyte migration and invasion in vitro and in vivo (16, 18, 32 , 37), we tested whether somatostatin was able to affect monocytes. 
Somatostatin effects on monocytes
Treatment of monocytes with 50 M somatostatin reduced KS cell product-induced migration by ϳ50% (Fig. 4a) . HIV-Tat is a potent inducer of monocyte migration. Again, somatostatin inhibited the response of monocytes to Tat (Fig. 4b) . Polarization of monocytes is an effective indicator of the activation of these cells toward a migratory stimulus. Monocytes treated with f-MLP or KS-CM show significantly increased polarization as compared with untreated controls. Simultaneous treatment with somatostatin inhibited polarization in response to KS-CM (Fig. 4c) . Treatment of monocytes with 50 M somatostatin inhibited monocyte migration to f-MLP by ϳ35%.
Monocytes appear to respond directly to somatostatin, suggesting these cells have somatostatin receptors. In fact, RT-PCR demonstrated the presence of the SSTR2, SSTR3, and SSTR5 somatostatin receptors on these cells (Fig. 4d) .
DISCUSSION
Inhibition of angiogenesis is a primary target for antineoplastic therapy, and molecules acting at different levels on the angiogenic cascade have been found to reduce or even suppress growth of certain tumors (1) .
Somatostatin has been proposed to be a potential antitumor agent. Although somatostatin is very effective in inhibiting tumor cell proliferation in vitro, in vivo treatments have been much less successful (see ref 38) . Endocrine tumors that express high levels of somatostatin receptors are the oncotypes most responsive to somatostatin (7, 8) . Recently, the antiproliferative activity of somatostatin in endocrine tumors has been proposed to be dependent on the SSTR-mediated activation of phosphotyrosine phosphatase activity (10) . Although occasional somatostatin receptors have been detected in nonendocrine tumors (39) , the mechanisms of the antiproliferative activity of somatostatin in many tumors has remained obscure. Limited preliminary data suggest that somatostatin may inhibit angiogenesis in the chick CAM (40, 41) , and somatostatin receptors have been reported to be expressed at high density on endothelial cells near tumors (42) . However, there are no reports on the effects of somatostatin on tumor-induced angiogenesis or on endothelial cells stimulated by tumorderived products.
Kaposi's sarcoma represents a prototype of tumor angiogenesis. Here we have provided evidence that somatostatin can inhibit the growth in vivo of Kaposi sarcoma tumors as well as angiogenesis in Matrigel pellets in vivo. Somatostatin also inhibited KS cell product-induced endothelial cell invasion of a reconstituted basement membrane (Matrigel) in vitro; however, migration in the absence of the barrier was not inhibited. To elucidate whether the in vivo effect was direct (on endothelial cells) or indirect (on monocyte/macrophage mediators), we studied the effects of somatostatin on endothelial cell growth, migration, and invasion of basement membranes. Cells of endothelial origin (EAhy926) were stimulated to grow by KS sarcoma products. Somatostatin dose-dependently inhibited KS-CM-induced growth. This effect was likely mediated by the somatostatin receptor subtype SSTR3, since it was the only somatostatin receptor to be identified in these cells by RT-PCR analysis. Moreover, the phosphotyrosine inhibitor vanadate (43) reverted this effect. These data suggest that activation of phosphotyrosine phosphatases by SSTR3, whose coupling with this transduction system has been reported (44) , is responsible for the inhibitory effects of somatostatin on EAhy926 cell proliferation. These data imply that somatostatin interferes specifically with the tyrosine kinase signaling pathways in endothelial cells closely associated with angiogenesis and endothelial cell invasion.
In contrast, somatostatin was not able to reduce Tat/TNF-␣-induced endothelial cell invasion in vitro, indicating that somatostatin might have different targets in the block of Tat/TNF-␣-induced angiogenesis. However, the activation of phosphotyrosine phosphatase activity appears in this case also to participate in the somatostatin effect, since coincubation with vanadate completely reverted the antiangiogenic activity of somatostatin.
A major mediator of tumor angiogenesis in vivo are monocytes. Infiltrated monocytes are able to produce survival factors, which, in turn, activate endothelial cells and favor vascularization of tumors. We therefore analyzed whether somatostatin is capable of affecting monocyte chemotaxis. We found that somatostatin was indeed able to reduce monocyte migration. This is in agreement with a previous study showing somatostatin inhibition of growth-hormone-induced monocyte chemotaxis (45) . To explain the biological effects of somatostatin on monocytes, we investigated the expression of its receptors. RT-PCR analysis demonstrated that monocytes express three subclasses of somatostatin receptors: SSTR2, 3, and 5. The KS-Imm cells express neither somatostatin receptors nor growth inhibition by somatostatin; therefore, the antitumor effect is clearly indirect, through the inhibition of vascular supply. As is thought to occur for angiostatin and endostatin (4, 5) , somatostatin behaves in this case as a 'pure' angiogenesis inhibitor. In addition, somatostatin demonstrated a multiple antiangiogenic activity, inhibiting endothelial cells both directly and indirectly through monocyte inhibition. This permitted the blockade of two different types of potent angiogenic stimulation and suggests that successful antiangiogenic therapies will need to affect multiple cell types. In summary, our data show that Kaposi's sarcoma tumor growth is inhibited by somatostatin and that angiogenesis is the target of inhibition. Somatostatin clinical trials in oncology so far have shown no clear benefit to the patient for nonendocrine tumors (38) . Our demonstration that somatostatin can act as a 'pure' antiangiogenic drug, affecting tumor cells that do not have somatostatin receptors, suggests that clinical trials of somatostatin in oncology should have a different design from those previously reported (see ref 38) . Antiangiogenic therapy should in fact be continuous, since in most cases antiangiogenic drugs are 'angiostatic' rather than cytotoxic (1) . It might be that somastostatin used as an adjuvant antiangiogenic treatment, administrated after or during conventional therapy (surgical, radiological and chemical), may result in benefit to the patient.
